2019
DOI: 10.1007/978-1-4939-9027-6_19
|View full text |Cite
|
Sign up to set email alerts
|

Metabolic Profiling of Live Cancer Tissues Using NAD(P)H Fluorescence Lifetime Imaging

Abstract: Altered metabolism is a hallmark of cancer, both resulting from and driving oncogenesis. The NAD and NADP redox couples play a key role in a large number of the metabolic pathways involved. In their reduced forms, NADH and NADPH, these molecules are intrinsically fluorescent. As the average time for fluorescence to be emitted following excitation by a laser pulse, the fluorescence lifetime, is exquisitely sensitive to changes in the local environment of the fluorophore, imaging the fluorescence lifetime of NAD… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
9
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 10 publications
(9 citation statements)
references
References 93 publications
0
9
0
Order By: Relevance
“…12,30,[32][33][34][35][36][37] These assays are of particular interest in measuring responses to treatment in various cancer pathologies, cancer being a metabolically heterogeneous pathology, being able to generate energy by oxidative phosphorylation (OXPHOS) and (often preferentially) by glycolysis. 9,[38][39][40][41] A third coenzyme, nicotinamide adenine dinucleotide (phosphate) [NAD(P)H], the phosphorylated form of NADH, cannot spectrally be differentiated from NADH, so this paper follows convention to describe the mixed lifetime/intensity signal as NAD(P)H. A heightened interest in expanding the application and simplification of this FLIM assay arises from its potential to test suitability and earliest response to drug treatment in cancer therapies. Chemotherapy response in animal models and patients typically take days or weeks; this in vitro assay has been shown to predict results in hours, 35 potentially helpful to devise more individualized treatment modalities for patients.…”
Section: Introductionmentioning
confidence: 99%
“…12,30,[32][33][34][35][36][37] These assays are of particular interest in measuring responses to treatment in various cancer pathologies, cancer being a metabolically heterogeneous pathology, being able to generate energy by oxidative phosphorylation (OXPHOS) and (often preferentially) by glycolysis. 9,[38][39][40][41] A third coenzyme, nicotinamide adenine dinucleotide (phosphate) [NAD(P)H], the phosphorylated form of NADH, cannot spectrally be differentiated from NADH, so this paper follows convention to describe the mixed lifetime/intensity signal as NAD(P)H. A heightened interest in expanding the application and simplification of this FLIM assay arises from its potential to test suitability and earliest response to drug treatment in cancer therapies. Chemotherapy response in animal models and patients typically take days or weeks; this in vitro assay has been shown to predict results in hours, 35 potentially helpful to devise more individualized treatment modalities for patients.…”
Section: Introductionmentioning
confidence: 99%
“…Importantly, FLIM is compatible with confocal or multiphoton laser scanning microscopy as well as wide-field illumination. To obtain more details from each methodology, readers may refer to the following excellent publications [138][139][140][141].…”
Section: Analysis Of Nadh Autofluorescence By Flimmentioning
confidence: 99%
“…Fluorescence lifetime imaging was extended to determine the concentration of NADH. 36 The assessment of mitochondrial activity through NADH autofluorescence by live cell microscopy gives a range of outputs reflecting the activity of ETC as well as substrate supply which is conceptually and practically appealing. 37…”
Section: Can Nad+ and Nadh Be Responsible For Mas?mentioning
confidence: 99%